Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

International Clinical Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 250-256

  Serretti, Alessandro ^a   Calati, Raffaella ^a   Massat, Isabelle ^h   Linotte, Sylvie ^b   Kasper, Siegfried ^e   Lecrubier, Yves ^f   Sens Espel, Roser ^d   Bollen, Joseph ^c   Zohar, Joseph ^g   Berlo, Jacques ^d   Lienard, Patricia ^d   De Ronchi, Diana ^a   Mendlewicz, Julien ^b   Souery, Daniel ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Sint Truiden Psychiatric Center   (Belgium)

^d DNA Vision Sa   (Belgium)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SHEBA MEDICAL CENTER   (Israel)

^h FNRS   (Belgium)

Author keywords

CYP1A2; CYP2C19; CYP2C9; CYP2D6; Cytochrome genes; Depression

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM EXTRACT; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TIANEPTINE; VENLAFAXINE; VILOXAZINE;

ADULT; AGED; ALLELE; ARTICLE; DISEASE RESISTANCE; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED;

EID: 69549135357     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832e5b0d     Document Type: Article

References (33)

1. American Psychiatric Association (2000). Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157:1-45.
2. Anderson GD (2008). Gender differences in pharmacological response. Int Rev Neurobiol 83:1-10.
3. Binder EB, Holsboer F (2006). Pharmacogenomics and antidepressant drugs. Ann Med 38:82-94.
4. Charlier C, Pinto E, Ansseau M, Plomteux G (2002). Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol 16:369-372. (Pubitemid 35470583)
5. De Leon J, Susce MT, Murray-Carmichael E (2006). The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 10: 135-151. (Pubitemid 43974591)
6. Faber MS, Jetter A, Fuhr U (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125-134.
7. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2000). SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2:CD001851.
8. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G (2008). CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:474-482.
9. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, et al. (2004). Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 60:329-336. (Pubitemid 39062319)
10. Guengerich FP (2008). Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83.
11. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. (Pubitemid 350116943)
12. Iwashima K, Yasui-Furukori N, Kaneda A, Saito M, Nakagami T, Sato Y, Kaneko S (2007). No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol 64:96-99. (Pubitemid 46934423)
13. Kato M, Serretti A (in press). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry.
14. Kirchheiner J, Seeringer A (2007). Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 1770:489-494. (Pubitemid 46136751)
15. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473. (Pubitemid 38903502)
16. Lotrich FE, Pollock BG, Kirshner M, Ferrell RF, Reynolds Iii CF (2008). Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 33:123-130.
17. Lynch T, Price A (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391-396. (Pubitemid 47219454)
18. Nemeroff CB, DeVane CL, Pollock BG (1996). Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320. (Pubitemid 26074705)
19. Normann C, Horn M, Hummel B, Grunze H, Walden J (2004). Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 37:134-138. (Pubitemid 38680333)
20. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2008). Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 3:e1872.
21. Preskorn SH (1998). Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol 12:S89-S97.
22. Ruhe HG, Booij J, v Weert HC, Reitsma JB, Franssen EJ, Michel MC, Schene AH (2009). Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 34: 999-1010.
23. Ryan ND, Puig-Antich J, Cooper T, Rabinovich H, Ambrosini P, Davies M, et al. (1986). Imipramine in adolescent major depression: plasma level and clinical response. Acta Psychiatr Scand 73:275-288. (Pubitemid 16116251)
24. Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG, et al. (2008). Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 13:597-605. (Pubitemid 351704935)
25. Serretti A, Masaki K, De Ronchi D, Kinoshita T (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12:247-257. (Pubitemid 46328503)
26. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68:1062-1070. (Pubitemid 47340327)
27. Spina E, Santoro V, D'Arrigo C (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206-1227.
28. StatSoft I: STATISTICA per Windows, StatSoft Italia srl, 1995.
29. Suzuki Y, Fukui N, Sawamura K, Sugai T, Watanabe J, Ono S, et al. (2008). Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol 28:325-328.
30. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2008). The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4-15.
31. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40. (Pubitemid 43050100)
32. World Health Organization. Impact of disorders. http://www.who.int/whr/ 2001/ chapter2/en/index3.html 2001
33. Yasui-Furukori N, Kaneda A, Iwashima K, Saito M, Nakagami T, Tsuchimine S, Kaneko S (2007). Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Am J Med Genet B Neuropsychiatr Genet 144B:724-727. (Pubitemid 47417199)